Most Favored Nation (MFN) drug pricing is just price controls by another name. Instead of openly capping what a drug can cost in the United States, MFN pegs U.S. reimbursement to the lowest price set by foreign governments, many of which directly cap prices. The result is the importation of failed European policies. Firms would no longer negotiate based on domestic supply, demand, and therapeutic value, but on political decisions made abroad. In practice, MFN sets a government-imposed ceiling tied to the most restrictive international benchmark, functioning exactly like price controls that have repeatedly backfired.
Price controls do not simply lower the price of a drug; they also reduce the resources pharmaceutical manufacturers have to reinvest in research and development. When expected returns fall, companies invest less in new medicines, resulting in fewer future treatments for patients. Europe’s decline from its former position as a leading pharmaceutical innovator was tied to the expansion of aggressive price regulation. Reference pricing schemes like MFN have also been associated with worsened health outcomes.
MFN would also reduce drug exports. Companies based in countries with strict price regulation tend to launch medicines in fewer markets than ones operating in less regulated systems. That dynamic compounds the problem by further shrinking the revenue base available to support new research.
Reduced revenue affects more than internal research budgets. Lower expected returns weaken investor incentives to allocate capital to pharmaceutical development rather than other industries, draining additional resources from future innovation.
Pharmaceutical companies frequently delay launches in low-price countries, or forgo launching there entirely, because those markets offer limited revenue potential. When larger countries adopt reference pricing schemes like MFN, the incentives to avoid low-price markets intensify. If Canadian prices were used to set U.S. reimbursement, manufacturers would have a strong incentive not to launch in Canada at all. The U.S. market is so much larger that foregoing Canadian sales could be less costly than accepting a sharply reduced U.S. price. That outcome would leave U.S. prices elevated, deprive Canadians of access to medicines, and still reduce global research resources.
The current MFN plans would also raise costs for privately insured patients. While the caps would apply to government programs such as Medicare and Medicaid, manufacturers would have incentives to offset lost public-market revenue by increasing prices in the private market. That cost shifting would put upward pressure on premiums and out-of-pocket spending for most Americans.
Lowering prices without undercutting innovation requires restoring competitive pressure, not imposing artificial ceilings. Competition depends on expanding options. Generics and biosimilars provide post-patent competition that reliably drives prices down—often by 80 percent or more—while preserving incentives to innovate and develop new medicines. Expanding patient access to these alternatives, particularly for biosimilars which compete with some of the most expensive medicines, lowers costs without sacrificing innovation, reducing access abroad, or shifting costs onto the privately insured. It would reduce spending in Medicare and Medicaid as well as in the private market.
Direct-to-consumer sales extend that logic by bypassing middlemen that add cost without adding value. Transparent cash pricing reduces administrative overhead and limits opportunities for insurers and pharmacy benefit managers to profit at patients’ expense. Unlike price controls, these reforms do not cap returns while a medicine’s patent is still active, delay launches, or push costs onto the privately insured. They increase competition in distribution while maintaining strong incentives to develop the next generation of therapies.
Patients do not need government-set prices; they need greater access to lower-cost medicines through competitive markets. Importing European-style price distortions that delay access and reduce future drug development is a costly mistake.
